Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00478686 · ClinicalTrials.gov registry record
Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 102
- Enrollment target
NCT00478686: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT00478686 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 102 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00478686 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 102 participants
- Enrollment target
Study Summary
The goal of this laboratory research study is to identify possible differences in a gene among patients with breast cancer that cannot be treated by surgery. Researchers want to find out if differences in this gene may increase the risk of side effects from capecitabine.
Interventions
- PROCEDURE Phlebotomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2007-05-23 |
| Est. Completion | 2017-05-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00478686
The ClinicalTrials.gov registry entry for NCT00478686 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Phlebotomy is the first listed.
NCT00478686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00478686 about?
NCT00478686 is a clinical study titled "Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine". The goal of this laboratory research study is to identify possible differences in a gene among patients with breast cancer that cannot be treated by surgery. Researchers want to find out if differences in this gene may increase the risk of side effects from capecitabine.
What is the current status of trial NCT00478686?
This trial is currently completed. The enrollment target is 102 participants. The study started on 2007-05-23. Estimated completion is 2017-05-02.
What interventions are being tested in trial NCT00478686?
The interventions under investigation include: Phlebotomy (PROCEDURE).
Who is sponsoring clinical trial NCT00478686?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.